A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Oncoimmunology
; 10(1): 1898105, 2021 03 26.
Article
in En
| MEDLINE
| ID: mdl-33796406
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cancer Vaccines
/
Melanoma
Limits:
Humans
/
Male
Language:
En
Journal:
Oncoimmunology
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: